Effects of bone drugs on dental health

Effects of bone drugs on dental health

Play all audios:

Loading...

The American Society for Bone and Mineral Research (ASBMR) has produced a report that examines the link between a class of widely prescribed drugs used to strengthen bones and osteonecrosis of the jaw (ONJ). The report, authored by an international, multidisciplinary task force, was convened by the ASBMR to look at the possible association between ONJ, a deterioration of the jawbone, and a class of drugs known as bisphosphonates, which in recent years have been linked to the condition. According to the American Dental Association, some 23 million Americans take oral bisphosphonates for osteoporosis. ONJ was first reported among cancer patients receiving high doses of bisphosphonate drugs as part of their treatment. The disorder appears as an area of exposed bone in the lower and upper jaw often developing after tooth extraction, mouth injury and dental surgery. Some cases occurred as a result of no known injury. According to Elizabeth Shane, co-chair of the task force and immediate past President of the ASBMR, ONJ is rare in people taking low dose oral bisphosphonates for osteoporosis but she added that more research was needed to identify the risk factors and determine if changing the dosing schedules of bisphosphonates could reduce the incidence of ONJ. 'This new research agenda will help fill the considerable gaps in knowledge regarding this disorder and the recommendations will provide guidance for health care professionals in their care of patients currently on bisphosphonate therapy,' she explained. The ASBMR task force formed in July 2006 is an international, multidisciplinary group of experts in the field including representatives from the United States National Institutes of Health and the Canadian Institutes of Health Research. Both published and unpublished data on the occurrence of ONJ were examined, a case definition was determined and a future research agenda was recommended. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Effects of bone drugs on dental health. _Br Dent J_ 203, 181 (2007). https://doi.org/10.1038/bdj.2007.763 Download citation * Published: 25 August 2007 * Issue Date: 25 August 2007 * DOI: https://doi.org/10.1038/bdj.2007.763 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

The American Society for Bone and Mineral Research (ASBMR) has produced a report that examines the link between a class of widely prescribed drugs used to strengthen bones and osteonecrosis


of the jaw (ONJ). The report, authored by an international, multidisciplinary task force, was convened by the ASBMR to look at the possible association between ONJ, a deterioration of the


jawbone, and a class of drugs known as bisphosphonates, which in recent years have been linked to the condition. According to the American Dental Association, some 23 million Americans take


oral bisphosphonates for osteoporosis. ONJ was first reported among cancer patients receiving high doses of bisphosphonate drugs as part of their treatment. The disorder appears as an area


of exposed bone in the lower and upper jaw often developing after tooth extraction, mouth injury and dental surgery. Some cases occurred as a result of no known injury. According to


Elizabeth Shane, co-chair of the task force and immediate past President of the ASBMR, ONJ is rare in people taking low dose oral bisphosphonates for osteoporosis but she added that more


research was needed to identify the risk factors and determine if changing the dosing schedules of bisphosphonates could reduce the incidence of ONJ. 'This new research agenda will help


fill the considerable gaps in knowledge regarding this disorder and the recommendations will provide guidance for health care professionals in their care of patients currently on


bisphosphonate therapy,' she explained. The ASBMR task force formed in July 2006 is an international, multidisciplinary group of experts in the field including representatives from the


United States National Institutes of Health and the Canadian Institutes of Health Research. Both published and unpublished data on the occurrence of ONJ were examined, a case definition was


determined and a future research agenda was recommended. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Effects of bone drugs on dental health. _Br Dent


J_ 203, 181 (2007). https://doi.org/10.1038/bdj.2007.763 Download citation * Published: 25 August 2007 * Issue Date: 25 August 2007 * DOI: https://doi.org/10.1038/bdj.2007.763 SHARE THIS


ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard


Provided by the Springer Nature SharedIt content-sharing initiative